[
  {
    "ts": "2025-11-13T01:27:00+00:00",
    "headline": "3 Healthcare Stocks Topping a 2025 List of Dividend Yields",
    "summary": "Turn health into wealth with these three high-yielding dividend stocks.",
    "url": "https://www.fool.com/investing/2025/11/12/3-healthcare-stocks-topping-a-2025-list-of-dividen/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "fa15a7d6-932b-30e4-9233-4ce308ec27b2",
      "content": {
        "id": "fa15a7d6-932b-30e4-9233-4ce308ec27b2",
        "contentType": "STORY",
        "title": "3 Healthcare Stocks Topping a 2025 List of Dividend Yields",
        "description": "",
        "summary": "Turn health into wealth with these three high-yielding dividend stocks.",
        "pubDate": "2025-11-13T01:27:00Z",
        "displayTime": "2025-11-13T01:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1e0f427fa53007e24b9457b0c759b3e6",
          "originalWidth": 1400,
          "originalHeight": 937,
          "caption": "A stethoscope sits atop $100 bills laid out on a table.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XgrBi89kZjh6dZFYMGo5OA--~B/aD05Mzc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1e0f427fa53007e24b9457b0c759b3e6.cf.webp",
              "width": 1400,
              "height": 937,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hHoMDrSXZL5QAlzVYfaoQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1e0f427fa53007e24b9457b0c759b3e6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/12/3-healthcare-stocks-topping-a-2025-list-of-dividen/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-healthcare-stocks-topping-2025-012700712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "XRAY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T14:45:38+00:00",
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
    "source": "The Fly",
    "provider": "yfinance",
    "raw": {
      "id": "8797ed93-cd75-34fe-b872-cf042d802372",
      "content": {
        "id": "8797ed93-cd75-34fe-b872-cf042d802372",
        "contentType": "STORY",
        "title": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
        "description": "",
        "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
        "pubDate": "2025-11-13T14:45:38Z",
        "displayTime": "2025-11-13T14:45:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec",
          "originalWidth": 1200,
          "originalHeight": 628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHTvjvqtNAYBPYViMXYCow--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 1200,
              "height": 628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3gfZRz3Jb2im4_aLYVn4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Fly",
          "url": "https://thefly.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DASH"
            },
            {
              "symbol": "SSTI"
            },
            {
              "symbol": "CRCL"
            },
            {
              "symbol": "NKE"
            },
            {
              "symbol": "KRRO"
            },
            {
              "symbol": "DLTR"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "COO"
            },
            {
              "symbol": "BKNG"
            },
            {
              "symbol": "AZO"
            },
            {
              "symbol": "LWAY"
            },
            {
              "symbol": "FAST"
            },
            {
              "symbol": "VITL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "RKT"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T14:40:02+00:00",
    "headline": "Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-144002451.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "7c864643-f304-324b-aeb5-85656acbb8fb",
      "content": {
        "id": "7c864643-f304-324b-aeb5-85656acbb8fb",
        "contentType": "STORY",
        "title": "Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2025-11-13T14:40:02Z",
        "displayTime": "2025-11-13T14:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2",
          "originalWidth": 900,
          "originalHeight": 469,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FhE.FTVPiyZE7qpXxRqaxQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2.cf.webp",
              "width": 900,
              "height": 469,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFRv_ZJmMJVPU2zxJKrzAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-144002451.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-144002451.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T08:00:00+00:00",
    "headline": "RNAi looked doomed to fail — until Alnylam’s science chief found a way",
    "summary": "Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.",
    "url": "https://www.pharmavoice.com/news/kevin-fitzgerald-alnylam-rna-chief-scientific-drug-pharma/805343/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "687269d1-d487-3c21-9b70-a6748e081d46",
      "content": {
        "id": "687269d1-d487-3c21-9b70-a6748e081d46",
        "contentType": "STORY",
        "title": "RNAi looked doomed to fail — until Alnylam’s science chief found a way",
        "description": "",
        "summary": "Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.",
        "pubDate": "2025-11-13T08:00:00Z",
        "displayTime": "2025-11-13T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/ebe272ab58bd5f4860f49994e2412f2a",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "PharmaVoice, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/faCzssBpuaIVME6M0juLqw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/ebe272ab58bd5f4860f49994e2412f2a.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CqL3QO_OKFjlEPfzRSbRjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/ebe272ab58bd5f4860f49994e2412f2a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/kevin-fitzgerald-alnylam-rna-chief-scientific-drug-pharma/805343/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rnai-looked-doomed-fail-until-080000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T18:46:00+00:00",
    "headline": "Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?",
    "summary": "Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.",
    "url": "https://finance.yahoo.com/news/cytokinetics-gains-11-4-week-184600041.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e127ba11-2bac-3d5a-97ea-a03fe7bad998",
      "content": {
        "id": "e127ba11-2bac-3d5a-97ea-a03fe7bad998",
        "contentType": "STORY",
        "title": "Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?",
        "description": "",
        "summary": "Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.",
        "pubDate": "2025-11-13T18:46:00Z",
        "displayTime": "2025-11-13T18:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OFzi8.fflc0QvY_fkj9xyQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XEcGARCYysPADgwWqEzSbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cytokinetics-gains-11-4-week-184600041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cytokinetics-gains-11-4-week-184600041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T18:45:00+00:00",
    "headline": "BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?",
    "summary": "Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.",
    "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-shines-q3-184500604.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "36b4a5e1-d651-337d-80df-dbf2e8a75489",
      "content": {
        "id": "36b4a5e1-d651-337d-80df-dbf2e8a75489",
        "contentType": "STORY",
        "title": "BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?",
        "description": "",
        "summary": "Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.",
        "pubDate": "2025-11-13T18:45:00Z",
        "displayTime": "2025-11-13T18:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-shines-q3-184500604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-shines-q3-184500604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]